EP4631527A1 — Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof
Assigned to Korea National Institute of Health · Expires 2025-10-15 · 1y expired
What this patent protects
The present invention relates to a peptide-based conjugate for mRNA delivery, which overcomes the limitations of existing lipid nanoparticles and is capable of safely and immediately responding to new variants of infectious diseases. mRNA binds to an RNA-binding peptide of the co…
USPTO Abstract
The present invention relates to a peptide-based conjugate for mRNA delivery, which overcomes the limitations of existing lipid nanoparticles and is capable of safely and immediately responding to new variants of infectious diseases. mRNA binds to an RNA-binding peptide of the conjugate and undergoes self-assembly by an amphipathic polypeptide or polymer to thereby form a peptide and mRNA complex nanoparticle. The nanoparticle and a pharmaceutical composition comprising same were confirmed to efficiently increase intracellular delivery of mRNA and exhibit a vaccine effect by mRNA.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.